Morphic Therapeutic
35 Gatehouse Drive A-2
Waltham
Massachusetts
02451
United States
Tel: 781-996-0955
Website: http://morphictx.com/
Email: info@morphictx.com
About Morphic Therapeutic
Morphic Therapeutic is a biotechnology company developing a new generation of oral integrin therapies. Drawing on discoveries made in the lab of Scientific Founder Tim Springer, Morphic was created in 2015 with co-founders Polaris Partners, T.A. Springer and Schrödinger, Inc., along with ShangPharma Investment Group.YEAR FOUNDED:
December 2015
LEADERSHIP:
CEO: Praveen Tipirneni, M.D.
Chief Development Officer: Alex Lugovskoy, Ph.D.
Vice President of Chemistry: Blaise Lippa, Ph.D.
Vice President of Finance and Operations: Robert Farrell, CPA
111 articles about Morphic Therapeutic
-
Morphic Appoints Dr. Simon Cooper as Chief Medical Officer
3/19/2024
Morphic Therapeutic today announced that Simon Cooper, M.B.B.S., has joined the Company as Chief Medical Officer.
-
Morphic to Participate in March 2024 Investor Conferences
3/5/2024
Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, announced its participation at investor conferences during the month of March.
-
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2023
2/22/2024
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the full year 2023.
-
Morphic to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Morphic Therapeutic (Nasdaq: MORF) today announced that Praveen Tipirneni, M.D., Chief Executive Officer of Morphic, has returned in full capacity from a previously announced temporary medical leave of absence and will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 3:45 PM PT/6:45 PM ET.
-
Morphic to Present at November 2023 Investor Conferences
11/10/2023
Morphic Therapeutic announced that its management team will participate in the upcoming Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference.
-
Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023
11/3/2023
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the third quarter 2023.
-
Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set
10/9/2023
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced it will host a webcast and conference call to discuss the complete results from the open-label EMERALD-1 Phase 2a study of MORF-057 in adults with moderate to severe ulcerative colitis.
-
Morphic Holdings Announces CEO Dr. Praveen Tipirneni to Take Temporary Medical Leave of Absence
9/26/2023
Morphic Holdings Inc. announced that Chief Executive Officer Dr. Praveen Tipirneni suffered an emergent medical event and is taking a medical leave of absence.
-
Despite meeting the primary endpoint and eliciting endoscopic improvements in ulcerative colitis, Morphic Therapeutic’s investigational pill underwhelmed investors with its stock plummeting.
-
Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023
9/22/2023
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the publication of an abstract discussing new EMERALD-1 phase 2a primary results.
-
Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference
8/29/2023
Morphic Therapeutic announced that Marc Schegerin, MD, COO & CFO, will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, September 6th at 8:00 AM ET.
-
Morphic to Present at the Canaccord Genuity 43rd Annual Growth Conference
8/9/2023
Morphic Therapeutic announced that Praveen Tipirneni, M.D., President and Chief Executive Officer, will take part in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference on Thursday, August 10, 2023 at 11:30 AM ET.
-
Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023
8/3/2023
Morphic Therapeutic, a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, reported corporate highlights and financial results for the second quarter of 2023.
-
Morphic to Present at the 2023 Jefferies Global Healthcare Conference
6/6/2023
Morphic Therapeutic, a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, announced that its management team will participate in the Jefferies Healthcare Conference, including a hosted fireside chat, on Wednesday, June 7, 2023.
-
Morphic to Present at 2023 RBC Capital Markets Global Healthcare Conference
5/12/2023
Morphic Therapeutic announced that its management team will participate in a Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference on Wednesday, May 17, 2023.
-
Morphic Presents New Biomarker Data at DDW 2023 Supporting MORF-057 Program in Ulcerative Colitis
5/11/2023
Morphic Therapeutic announced the presentation of new preclinical data in the MORF-057 IBD development program that are consistent with previous findings and add new support to mechanistic understanding of the molecule’s activity in a nonhuman primate model of ulcerative colitis.
-
Morphic Therapeutic Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
5/5/2023
Morphic Holding, Inc. announced the closing of an underwritten public offering of 6,133,334 shares of its common stock at a price to the public of $45.00 per share, which includes 800,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock.
-
Morphic Therapeutic Announces Pricing of $240.0 Million Public Offering
5/3/2023
Morphic Holding, Inc., a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, announced the pricing of an underwritten public offering of 5,333,334 shares of its common stock at a price to the public of $45.00 per share.
-
Morphic Therapeutic Announces Proposed Public Offering - May 02, 2023
5/2/2023
Morphic Holding, Inc., a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, announced a proposed underwritten public offering of its common stock.
-
Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures
4/25/2023
Morphic Therapeutic today reported positive topline data from the main cohort of the open-label EMERALD-1 Phase 2a study of MORF-057, an oral small molecule inhibitor of the α4β7 integrin, in adults with moderate to severe ulcerative colitis (UC).